

UNITED STATES LEPARTMENT OF COMMERCE Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS

Washington, D.C. 20231

 APPLICATION NO.
 FILING DATE
 FIRST NAMED INVENTOR
 ATTORNEY DOCKET NO.

 08/813,950
 03/03/97
 ASSMUS
 M
 583-252-0-FW

IM11/1014

EXAMINER SELLERS, R

OBLON SPIVAK MCCLELLAND MAIER AND NEUSTADT 1755 JEFFERSON DAVIS HIGHWAY FOURTH FLOOR ARLINGTON VA 22202

ART UNIT PAPER NUMBER
1712 24

DATE MAILED:

10/14/98

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

Application No.

Applicant(s)

08/813,950

Robert Sellers

Examiner

Group Art Unit 1712



Office Action Summary

X Responsive to communication(s) filed on Oct 8, 1998	•
This action is FINAL.	محمداه ما معادم در المحمد و بالمحمد المحمد المحمد المحمد المحدد ا
 Since this application is in condition for allowance except for formal in accordance with the practice under Ex parte Quayle, 1935 C.D. 	11, 400 0.01 2.0
A shortened statutory period for response to this action is set to expire is longer, from the mailing date of this communication. Failure to response application to become abandoned. (35 U.S.C. § 133). Extensions of 137 CFR 1.136(a).	
Disposition of Claims	is/are pending in the application.
X Claim(s) 3, 5, 7, 9, 11, 13, 15, and 17-24	
Of the above, claim(s) 3, 5, 7, 9, 11, 13, and 15	is/are withdrawn from consideration.
Claim(s)	is/are allowed.
X Claim(s) 17-24	is/are rejected.
☐ Claim(s)	is/are objected to.
Claim(s)	are subject to restriction or election requirement.
Application Papers See the attached Notice of Draftsperson's Patent Drawing Review is/are objected to i	by the Examiner. is _approved _disapproved. 35 U.S.C. § 119(a)-(d). priority documents have been hational Bureau (PCT Rule 17.2(a)).
 Notice of References Cited, PTO-892 ☒ Information Disclosure Statement(s), PTO-1449, Paper No(s). ☐ Interview Summary, PTO-413 ☐ Notice of Draftsperson's Patent Drawing Review, PTO-948 ☐ Notice of Informal Patent Application, PTO-152 	24
SEE OFFICE ACTION ON THE F	FOLLOWING PAGES

Application/Control Number: 08/813,950

Art Unit: 1712

The finality of the rejection mailed July 27, 1998 is hereby withdrawn in response to the Information Disclosure Statement filed June 8, 1998.

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless --

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 17-24 are rejected under 35 U.S.C. 102(b) as being anticipated by De Haan et al.

Example I in column 7, lines 8-22, the restraining phase, shows the melt extrusion of 83% by weight of Eudragit RSPM (an acrylic polymer within the ambit of claim 20 according to page 11, lines 3-8 of the specification) and 17% by weight of cetyl alcohol (a fatty alcohol embraced by the claimed flow improver as confirmed by page 14, line 6 of the specification). The chloroform blended with cetyl alcohol is evaporated prior to melting of the mass and extrusion. The mixture of Eudragit RSPM and cetyl alcohol is inherently non-homogeneous based on the types and amounts of acrylic polymer and flow improver within the claimed limits.

Application/Control Number: 08/813,950

Art Unit: 1712

The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.

Claims 17-24 are rejected under 35 U.S.C. 103(a) as being unpatentable over Mueller et al, Seth and European Patent No. 204,596.

Mueller et al discloses the melt extrusion (col. 3, lines 9-15) of at least 6% by weight (col. 2, lines 1-16) of an acrylic copolymer such as Eudragit RS (col. 4, Example 1) and as much as 30% by weight of pharmaceutical auxiliaries such as polyethylene glycols (col. 3, line 3 which is a suitable species of flow improver according to page 14, line 8 of the specification). It is a matter of ordinary skill in the art to employ a particular pharmaceutical auxiliary such as polyethylene glycols in order to impart a plasticizing effect which by definition improves the flow properties of the formulation.

Seth in column 6, Table 1, Examples 1 and 2 exhibits the melt mixing (col. 5, line 57 to col. 6, line 12) of 62% by weight of an Eudragit S 100 acrylic copolymer and 38% by weight of a polyethylene glycol 300-stearate (col. 6, line 39 which is an acceptable flow improver as indicated on page 14, line 21 of the specification). Although it is stated in column 4, lines 47-50 that a homogeneous solution is formed, no difference is seen between the prior art and claimed compositions based on the use of identical types and amounts of acrylic polymer and polyethylene glycol stearate.

Application/Control Number: 08/813,950

Art Unit: 1712

The specification on page 6, lines 15-25 reveals that non-homogeneity is determined by the appearance of a film of the blend in a common solvent. There is no evidence distinguishing the claimed non-homogeneity throughout the claimed proportion ranges of acrylic plastic and flow improver over the closest prior art combination of Eudragit S 100 and polyethylene glycol 300-stearate wherein any data is presented objectively not by descriptors but by scientifically verifiable means such as differential thermoanalysis by DSC measurement (specification, page 7, lines 15-19).

The arguments pertaining to the European patent presented in the response filed October 8, 1998 (Paper No. 25) have been considered but are unpersuasive.

The specification on page 6, lines 15-18 states that "The mixture of the components A and B, in accordance with the invention, is regarded as non-homogeneous, if the components A and B are not compatible in the quantities used." However, page 7, lines 20-22 proposes that "Components A and B are essentially miscible in the melt, recognizable in the optical clarity of the melt." Page 11, lines 13-17 indicates "Flow improver B includes substances that can be mixed in an essentially homogeneous manner with the melt of polymer A . . . "

Application/Control Number: 08/813,950 Page 5

Art Unit: 1712

The disclosure describes the miscibility and homogeneity of the acrylic plastic and flow improver in the melt which encompasses the melt extrusion mixture of Eudragit RSPM and Precirol (i.e. glycerol palmito-stearate) of the European patent. Based on the description on page 6, line 23 to page 7, line 8 that "in the solidified melt, components A and B are present as separate phases," the composition of the European patent inherently exibibits the claimed non-homogeneity once the melt solidifies.

European Patent Nos. 40,590 and 502,642 are directed to Eudragit acrylic copolymers and cetyl alcohol or polyethylene glycol, respectively, which are mixed in an organic solvent as opposed to the claimed hot-melt mixing. Shukla et al sets forth a formulation of a wax such as glycerol fatty acid esters and additives including Eudragit acrylic polymers within an extensive list wherein no example with Eudragit is prepared.

Any inquiry concerning this communication should be directed to Robert Sellers at telephone number (703) 308-2399 (Fax no. (703) 305-5408).

ROBERT E. SELLERO PRIMARY EXAMINER

GROUP 150 ___

rs

10/14/98